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Prediction of left ventricular mass changes after renal transplantation
by polymorphism of the angiotensin-converting.enzyme gene. Cardiac
complications are the main cause of death in renal transplant patients and
left ventricular hypertrophy (LVH) may play a determinant role. An
association between the insertion-deletion polymorphism of the angioten-
sin-converting enzyme (ACE) gene and LVH has been reported in adults.
However, little is known about the genetic influence on left ventricular
mass changes after renal transplantation, where unique environmental
factors, such as cyclosporine A (CsA) and prednisone treatment concur. In
fact, CsA treatment has recently been associated with the development of
LVH. We prospectively determined the changes on cardiac structure and
function, assessed by echocardiographic criteria, in 38 consecutive nondi-
abetic adults who received a cadaveric renal allograft. They were treated
with cyclosporine and prednisone and maintained a good renal function
during the follow-up. Echocardiographic studies (M-mode, 2-B and color
flow Doppler) were performed without previous knowledge of the genetic
typing, at the time of transplantation, and 6 and 12 months later. ACE
alleles were typed using a PCR-based assay developed to ascertain the
presence of an insertion (1)—deletion (D) polymorphism in intron 16 of
the ACE gene. Patients with the so-called "unfavorable" DD genotype
(N = 16) were compared with the ID or II genotypes (N = 22). The
baseline left ventricular mass index was similar in patients with or without
the unfavorable DD genotype (X SE; 166.6 10.4 vs. 181.3 9 gIm2,
respectively) and a similar proportion fulfilled the criteria of LVH (88%
vs. 82%, respectively). The mean percent increase of the left ventricular
mass index 12 months after renal transplantation was significantly higher
in patients with the DD genotype compared to those with other genotypes
(21.3 7.9 vs. —0.08 4.9%, respectively; P < 0.05). As a result, 94% of
DD patients showed LVH at the end of the follow-up, while 68% of the
ID or II patients had LVH (P < 0.05). In addition, the left ventricular
ejection fraction significantly increased only in ID or II patients 12 months
after transplantation with respect to baseline (ID/Il patients, 70.4 1.5 vs.
63.7 1.8%; P < 0.05; DD patients, 68.3 2.1 vs. 63.3 2.9%). The
deleterious effect of the DD genotype was independent of blood pressure,
biochemical parameters, weight gain, and cumulative steroids dosages or
cyclosporine levels. In conclusion, genetic factors determine the changes
on cardiac structure and function after renal transplantation. The pres-
ence of the DD genotype of the ACE gene is a marker associated with an
elevated risk of LVH in this population.
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Cardiovascular complications are the major cause of late mor-
bidity and mortality in transplant recipients [1]. Coronary artery
disease is the principal cause of death after renal transplantation,
with a relative mortality risk 3- to 10-fold higher than that found
in the normal population [1, 2]. Among the many factors involved
in the pathogenesis of these complications [1, 3], left ventricular
hypertrophy (LVH) is considered a major independent risk factor
for cardiac disease [4]. In addition, LVH is the most common
cardiovascular change observed in end-stage renal disease pa-
tients (>60%) and appears to be an important determinant of
survival [5—7].
The effect of renal transplantation on LVH is a subject of
controversy. Prospective echocardiographic studies have demon-
strated regression of LVH after successful renal transplantation
[8—11], while others have not observed such an effect [12, 13].
Blood pressure seems to play a determinant role in LVH evolu-
tion after successful renal tranplantation [10, 11].
Experimental studies suggest that angiotensin II may stimulate
cardiac protein synthesis [14, 15]. Angiotensin-converting enzyme
(ACE) is a key enzyme in the production of angiotensin II and
thus may participate in the modulation of cardiac growth [16]. The
cloning of the ACE gene has made it possible to identify an
insertion (1)—deletion (D) polymorphism in intron 16 that appears
to affect the level of serum ACE activity [17, 18]. As a matter of
fact, patients with the DD genotype show the highest ACE levels
and an elevated risk of LVH [19, 20], idiopathic dilated cardio-
myopathy [21] and myocardial infarction [22]. However, the
influence of this genetic factor on the changes of left ventricular
mass after renal transplantation has not been explored.
In the present study, we measured the morphological and
functional cardiac changes assessed by echocardiography in 38
consecutive non-diabetic renal transplant recipients, from whom
the ACE genotype was known. We investigated a possible asso-
ciation between an insertion-deletion (ID) polymorphism of the
ACE gene and left ventricular mass and function.
Methods
Patients
From June 1993 to June 1994, we studied 38 consecutive
nondiabetic patients after successful renal cadaveric graft (serum
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creatinine < 2.5 mg/dl or < 221 jLmol/liter during the study
follow-up). All patients were followed in the transplant clinic of
the Hospital Universitario, and they had been on maintenance
dialysis before transplantation for 1 to 180 months. None of the
patients showed clinical features of heart failure or significant
valvular disease, as determined by echocardiography, during the
course of the study. Hypertension was defined as a systolic and
diastolic blood pressure > 150/90 mm Hg. It was considered
severe when two or more antihypertensive drugs were required for
adequate blood pressure control. None of the patients included in
this study received angiotensin-converting enzyme inhibitors. Im-
munosuppression consisted of antilymphoblastic globulin
(Merieux, Lyon, France) for induction and prednisone (0.3 mg/kg
body wt/day during the first three months, with a gradual reduc-
tion to 10 mg/day by one year), cyclosporine, and azathioprine
(1.25 to 1.5 mg/kg body wt) for maintenance. Recipients older
than 50 years did not receive azathioprine. Cyclosporine was
started at 8 mg/kg body wt/day when plasma creatinine was < 3
mg/dl (265.2 .tmol/liter), and then adjusted according to the total
blood levels [23]. Episodes of acute rejection were initially treated
with three boluses of 500 mg of intravenous methyiprednisolone.
Resistant episodes were treated with a 10-day course of OKT3 (5
mg/day; Ortho Pharmaceutical, NJ, USA). Table 1 summarizes
the clinical, immunosuppression, and renal function data accord-
ing to the ACE genotype. In order to assess the genetic influence
on morphological and functional cardiac changes after renal
transplantation, patients with the (DD) genotype were compared
to those with other genotypes (ID or II).
The study was approved by the Ethics Committee of the
Hospital Universitario.
Study design
Echocardiographic parameters, clinical and biochemical data
were measured at the time of renal transplantation, after the
dialysis session in preparation for surgery, and 6 and 12 months
thereafter.
Laboratory measurements
Serum creatinine and other biochemical parameters were mea-
sured by means of a computerized autoanalyzer (Hitachi 717,
Boehringer Manheim, Germany). Total blood cyclosporine levels
were quantified by FPIA assay using a monoclonal antibody
(Abbot, IL, USA).
Echocardiographic technique and data collection
M-mode, two-dimensional, and color flow Doppler echocardio-
grams were performed by the same examiner (J.L.) without
previous knowledge of the genetic typing. Each echocardiographic
tracing was coded and interpreted at random by a second expe-
rienced observer (A.B.), who was unaware of the subject identi-
fication and clinical characteristics. In our laboratory, interob-
server variability for these measurements in ten repeated studies
averaged < 10% (data not shown). Echocardiograms were ob-
tained with the patient in the left decubitus position with 30° of
head inclination, using an ultrasonoscope (Aloka SSZ-203) with
either a 2.5 or a 3.5 MHz transducer. The left ventricular
echocardiogram was recorded following a standard protocol at or
just below the tips of the mitral valve leaflets, with the transducer
applied to the third or fourth intercostal space. Measurements of
cavities and cardiac walls were undertaken following the recom-
DD
(N=16)
ID and II
(N=22)
Age years
Sex M/F
Dialysis duration months
46.2 4.1
13/3
32.3 10.7
45.2 2.9
13/9
26.4 7.3
Total hypertensive patients (%)
Pretransplantation
6 months post-transplantation
12 months post-transplantation
12 (75%)
16 (100%)
15 (93.7%)
16 (72.7%)
19 (86.3%)
18 (81.8%)
N patients with severe hypertension,
receiving two or more drugs %
Pretransplantation
6 months post-transplantation
12 months post-transplantation
6 (37.5%)
9 (56.2%)
10 (62.5%)
8 (38%)
11(52%)
12 (57%)
Systolic blood pressure mm Hg
Pretransplantation
6 months post-transplantation
12 months post-transplantation
144.4 4.9
146.4 4.2
143.7 5.7
144.3 3.3
146.4 4.1
148.9 4.3
Diastolic blood pressure mm Hg
Pretransplantation
6 months post-transplantation
12 months post-transplantation
87.5 2.8
92.6 2
91.1 2
87.1 1.4
90 2.6
91.3 2.7
Mean arterial tension mm Hg
Pretranspiantation
6 months post-transplantation
12 months post-transplantation
106.4 3.2
110.5 2.3
108.6 2.7
106.2 1.7
108.9 2.8
110.5 2.8
Cumulative Steroids g
12 months post-transplantation 5.6 0.3 5.9 0.3
Body mass index kg/m2
Pretransplantation
6 months post-transplantation
12 months post-transplantation
24.7 1.3
27.8 1b
29.3 1•2h
24.2 0.8
26.9 0.9k'
28.2 0.9°''
CsA levels ng/ml
6 months post-transplantation
12 months post-transplantation
258.5 38.7
229.9 24.3
201.2 10.8
211.6 12.1
Serum creatinine mg/dl
6 months post-transplantation
12 months post-transplantation
1.5 0.15
1.48 0.13
1.5 0.13
1.6 0.14
Hematocrit %
Pretransplantation
6 months post-transplantation
12 months post-transplantation
32.3 1.5
40.6 1•7b
43.3 22b
32.7 1.1
395
41.6 l.5'
mendations of the American Society for Echocardiography [24].
Left ventricular mass (LVM) was determined according to the
method of Devereux and Reichek [25] and indexed to body
surface area to yield the left ventricular mass index (LVMJ). The
cut-off level defining left ventricular hypertrophy was LVMI >
143 g/m2 in men and LVMI > 102 g/m2 in women [26]. Left
ventricular systolic function was assessed by the ejection fraction,
which was calculated as LVEDV — LVESV/LVEDV, where
LVEDV and LVESV are end-diastolic and end-systolic volumes
both calculated by the formula of Teichholz et al [27]. The
Doppler echocardiography was performed immediately after the
M-mode examination. Transmitral flow velocity signals were
recorded simultaneously with an electrocardiogram and a phono-
cardiogram. The following measurements were obtained: maximal
Table 1. Demographic, clinical and immunosuppresion data
Conversion factors to SI units: Creatinine 88.4 (j.mol/1iter).
° P < 0.05 vs. 6 months
h P < 0.01 vs. baseline
..— .-.-,
Fig. 1. Analysis of the insertion-deletion
polymorphism at the ACE locus by PCR. DNA
amplification with ACE-specific primers
spanning the intron 16 polymorphic sequence
results in either a 597 bp (I) or a 319 bp (D)
fragment DNA. Samples 1, 4 and 9, correspond
to homozygous DD individuals, while lane
numbers 2, 3, 5, 6, 7 and 8 represent ID
heterozygotes. Lane M is the molecular weight
standard. Ethidium bromide staining of 5%
aciylamide gel electrophoresis.
early (peak E) and late (peak A) diastolic flow velocities in
cm/second, deceleration time of flow velocity in early diastole
(DT) and left ventricular isovolumic relaxation time (LVIRT) in
mseconds. In addition, the ratio of peak flow velocity in early
diastole to peak flow velocity during atrial systole (E/A) was
calculated.
The mean measurement of three to five consecutive cardiac
cycles was determined for each of these indexes.
Genomic typing of the ACE deletion/insertion polymorphism
The previously described D and I alleles of the ACE gene were
ascertained by polymerase chain reaction (PCR) amplification of
a fragment of intron 16 of the ACE gene [28]. DNA was purified
from 3 ml of blood by proteinase K digestion, phenol extraction
and ethanol precipitation, following standard protocols [29].
Approximately 0.1 ig DNA was amplified with primers hace3s,
5'GCCCTGCAGGTGTCTGCAGCATGT3', and hace3as,
5 'GGATGGCTCTCCCCGCC'FTGTCTC3', which yield PCR
products of 319 bp and 597 bp for the D and I alleles, respectively.
PCR conditions included: 10 mivi Tris-HC1, pH 9.0, 50 mvt KC1,
1.5 mM MgCI2, 0.1% Triton X-100, 0.1 mM dNTPs, 0.5 1LM each
primer, and 1 U Taq DNA polymerase. A Perkin-Elmer 480
thermal cycler was used to carry out 30 amplification cycles with
the following temperature profile: 94°C (1 mm), 62°C (1 mm), and
72°C (1 mm). Ten microliters of the amplification product were
resolved by electrophoresis in 5% polyaciylamide gels and visu-
alized under UV light after staining with 0.5 rg/ml ethidium
bromide (Fig. 1).
All samples yielding amplification of the D allele exclusively
(and therefore potentially typed as DD) were subject to a second
independent amplification, as described by Lindpaintner et a!
[28]. Briefly, samples were amplified under the same buffer
conditions as described above, except for the use of primers
specific for the sequence inserted in intron 16 of the I allele, and
a temperature profile of 94°C, 67°C, 72°C, one minute each. The
primer sequences are: hace5a, 5 '-TGGGACCACAGCGCCCGC-
CACTAC-3', and hace5c, 5 '-TCGCCAGCCCTCCCATGC-
CCATAA-3', which result in an amplification product of 335 bp
only in the presence of an I allele.
We also estimated the allele frequencies for the I/D polymor-
phism at the ACE locus among all the renal transplant patients in
our DNA bank (N = 135), as well as among 146 second year
medical student volunteers. For the renal transplant population
sample, high molecular weight DNA was purified from 3 ml blood
as described above, while crude DNA lysates were prepared from
volunteers' mouth washes. Briefly, cells were collected in 10 ml
saline, and pellets were resuspended in 100 tl of lysis buffer
containing 50 mM Tris-HC1, pH 8.3, 50 mM KC1, 2.5 mvi CI2Mg,
0.45% Tween 20, 0.45% Nonidet P-40, 0.1 mg/ml gelatin and 0.06
.rg/ml proteinase K. After two hours, digestion at 55°C, residual
proteinase K was heat-inactivated at 95°C for 10 minutes, and 10
jd of the crude lysate were used for each PCR assay.
Statistical analysis
Results are expressed as mean SE. Friedman two-way
ANOVA by ranks test was used to compare echocardiographic
measurements at the time points of the study. Pairwise compari-
sons were performed by the Wilcoxon signed-ranks test with
adjusted degrees of freedom. Group mean values were compared
by the Mann-Whitney U test; Chi-square with Yates' correction or
Fisher's exact test were used to compare proportions. Linear
regression analysis was used to compare changes in echocardio-
graphic measurements with different clinical and biochemical
parameters. A P value less than 0.05 was considered significant.
Results
The distribution of the DD, ID, and II genotypes in our patients
was 42% (N = 16), 52.6% (N = 20), and 5.2% (N = 2),
respectively. The frequencies of the D and I alleles were 0.68 and
0.32, respectively.
Among the 135 transplanted patients currently in our DNA
bank, the alleles frequencies (D = 0.64%; I = 0.36%) and
genotype distribution (DD = 39.2%; ID = 50.3%; II = 10.3%)
are similar to those found in the study group. Also, among the 146
medical student volunteers, the alleles frequencies (D = 0.65%;
I = 0.35%) and genotype distribution (DD = 39.7%; ID = 50%;
II = 10.2%) are similar to those found in the study group. In all
groups studied, the genotype distributions were not significantly
different from the predictions of the Hardy-Weinberg model for
their respective allele frequencies.
No patient suffered cardiac failure or angina pectoris during the
follow-up. After renal transplantation, all patients showed an
important increase in weight and hematocrit. The prevalence of
hypertension at baseline, 6, and 12 months after renal transplan-
tation was similar in both groups. In addition, the number of
patients with severe hypertension was not different during the
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study (Table 1). All hypertensive patients received nifedipine as a
first line drug, and diuretics, beta-blockers or a,-adrenoceptor
antagonists (doxazosin) were sequentially added as clinically
indicated, in order to obtain an adequate blood pressure control.
The proportion of patients under different antihypertensive drugs
was similar in both groups at baseline, and 6 and 12 months after
transplantation (DD vs. ID or II: beta-blockers, 21% vs. 22%;
diuretics, 14.2% vs. 10%; doxazosin, 28% vs. 26%). Moreover,
systolic, diastolic and mean arterial pressures were not different
between the two groups during follow-up (Table 1).
Echocardiographic data from both groups are summarized in
Table 2. Baseline measurements were similar in both groups.
Interestingly, 88% of DD patients and 82% of ID or II patients
met the criteria of LVH. However, 12 months after renal trans-
plantation a significant increase in interventricular septal thick-
ness, posterior wall thickness, and left ventricular mass was only
seen in patients with (DD) genotype (Table 2 and Figs. 2 and 3).
As a matter of fact, DD patients showed a higher percent increase
from baseline in left ventricular mass index after 12 months of
transplantation (Table 2), as compared to patients with ID or II
genotype. As a result, twelve months after renal transplantation,
LVH was present in 94% of DD patients and in only 68% of
patients with the ID or H genotype (P < 0.05). Finally, left
ventricular ejection fraction significantly improved only in patients
with the ID or II genotype 12 months after grafting (Table 2). No
correlation was found between left ventricular mass and age, body
mass index, hematocrit values, arterial pressure, cumulative ste-
roids or cyclosporine levels.
Table 3 shows Doppler echocardiographic data during the
follow up period. No differences were found between the two
groups for maximal early (peak E) and late (peak A) diastolic flow
velocities, E/A ratio and deceleration time at baseline, and 6 and
12 months thereafter. However, patients with favorable genotype
(ID and II) showed significant improvement of left ventricular
isovolumic relaxation time during follow-up, which was not ob-
served in DD patients. In addition, this parameter was higher in
DD patients at baseline and during follow-up, as compared to
patients with favorable genotypes (Table 3 and Fig. 4).
Discussion
Prospective echocardiographic studies have demonstrated a
significant regression of LVH in diabetic and nondiabetic patients
after renal transplantation [8—10, 30]. In contrast, other authors
have found that LVH persists, mainly in patients with increased
blood pressure, after successful renal transplantation [11—13].
This observation and the fact that many subjects with LVH have
normal blood pressure suggest that the factors traditionally asso-
ciated with LVH may be less important than was previously
assumed and/or that the genetic background contributes to the
development of LVH. Among such genetic factors a major role
has been attributed to the ACE alleles [19, 20]. We used a PCR
procedure previously reported to accurately determine the ACE
genotype [28], and investigated its role in predicting left ventric-
ular mass changes after renal transplantation. In order to mini-
mize coexistent abnormalities, we included only nondiabetic pa-
tients with an acceptable renal function throughout the study. At
present, echocardiography represents the safest and most reliable
noninvasive procedure for the study of left ventricular hypertro-
phy [4]. Thus, we investigated changes of cardiac structure and
function by echocardiography after 6 and 12 months of renal
DD
(N=16)
ID an
(N=
d II
22)
LVESD mm
Baseline
6 months post-transplant
12 months post-transplant
LVEDDmm
Baseline
6 months post-transplant
12 months post-transplant
LAD mm
Baseline
6 months post-transplant
12 months post-transplant
LVEF %
Baseline
6 months post-transplant
12 months post-transplant
IVST mm
Baseline
6 months post-transplant
12 months post-transplant
PWTmm
Baseline
6 months post-transplant
12 months post-transplant
LVM g
Baseline
6 months post-transplant
12 months post-transplant
LVM increase %
6 months post-transplant
12 months post-transplant
LVMI g/m2
Baseline
6 months post-transplant
12 months post-transplant
LVMI increase %
6 months post-transplant
12 months post-transplant
Patients with LVH %
Baseline
12 months post-transplant
30.2 0.7 31.9 2.3
31.7 1.1 32.5 2.01
29.2 0.9 30.5 1.2
47.8 1.04 50 1.4
50 0.9 48.6 1.5
48.2 1.6 50.1 1.2
36.5 1.04 37.5 1.4
37.5 1.3 38.1 1.6
37.2 1.4 38.3 1.1
63.3 2.9 63.7 1.8
65.9 2.3 65.5 2.3
68.3 2.1 70.4 1.5"
12.1 0.7 12.3 0.4
13.08 1.1 13.1 0.5
14.7 1.5' 12.6 0.5
12.1 0.6 12.3 0.4
12.7 1.1 12.4 0.5
14.8 1.3" 12.6 0.5
277.5 17.5 305.9 18
333.7 39.9 311.5 20.4
366 41.7" 314.2 19.3
10.7 6.7 2.4 4.6
30.8 8.8 5.6 55C
166.6 10.4 181.3 9.1
189.4 21.3 178 10.7
201.5 21.6a 176.9 9.4
5.1 6.4 —1.7 4.3
21.3 7.9 —0.08 49C
14 (88%) 18 (82%)
15 (94%) 15 (68%y
Abbreviations are: LVESD, left ventricular end-systolic diameter;
LVEDD, left ventricular end-diastolic diameter; LAD, left auricular
diameter; LVEF, left ventricular ejection fraction; IVST, interventricular
septal thickness; PWT, posterior wall thickness; LVM, left ventricular
mass; LVMI, left ventricular mass index; LVH, left ventricular hypertro-
phy.
P < 0.05 vs. Baseline
"P < 0.01 vs. Baseline
P < 0.05 vs. DD
transplantation. Our study strongly suggests that genetic predis-
position may substantially contribute to the development or
impairment of left ventricular hypertrophy in renal transplant
patients immunosuppressed with cyclosporine.
The observation that the genetic background contributes to the
development of cardiac hypertrophy was obtained by linkage
studies in twins [31]. Other authors have also reported that over
Table 2. Echocardiographic parameters at baseline, and at 6 and 12
months after grafting
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1201±24
189±21 8 *
81
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6
Time, months
Fig. 2. Left ventricular mass index in DD patients at baseline, and 6 and 12
months after renal transplant. *D < 0.05 versus baseline.
j181±9 I178±10 I177±9
i
V
6
Time, months
Fig. 3. Left ventricular mass index in patients with genotype ID or II at
baseline, and 6 and 12 months after renal transplant.
Table 3. Doppler echocardiographic measurements at baseline, and at
6 and 12 months after renal transplant
DD
(N = 16)
ID and II
(N = 22)
-
Peak E cm/sec
Baseline 61 4.3 63 3.2
6 months post-transplant 60 8 61 4
12 months post-transplant 66 9 67 4.4
Peak A cm/sec
Baseline 67 3 63.6 4
6 months post-transplant 54 5' 64 5
12 months post-transplant 66 9" 67 4
E/A ratio
Baseline 0.96 0.08 1.06 0.08
6 months post-transplant 1.2 0.3 1.05 0.12
12 months post-transplant 1.07 0.16 1.09 0.09
DT msec
Baseline 175.7 21.2 167.8 18.2
6 months post-transplant 180 25 174.1 12.9
12 months post-transplant 170 21.5 175.5 14.2
LVIRT msec
Baseline 172 13.05 143.4 3.8c
6 months post-transplant
12 months post-transplant
177.6 15.6
161.8 14.6
137.5
134 4.8c
Abbreviations are: Peak E, peak of early diastolic flow velocity; peak A,
peak of late diastolic flow velocity; E/A ratio, ratio of early to late diastolic
flow; DT, deceleration time of E wave; LVIRT, left ventricular isovolumic
relaxation time.
a p < 0.05 vs. baseline
h P < 0.05 vs. 6 months
P < 0.05 vs. DD
6
Time, months
Fig. 4. Left ventricular isovolumic rela.xation time (LVIRT) in both groups
of patients at baseline, and 6 and 12 months after renal transplant. Symbols
are: (0) patients with DD genotype; (Y) patients with ID or II genotypes;
*P < 0.05 versus baseline; p < 0.05 versus ID or II patients.
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60% of the variability in left ventricular mass can be explained by
heritable factors [32]. Likewise, Marian et al [20J observed a high
frequency of DD genotypes in patients with hypertrophic cardio-
myopathy and in families with a strong histosy of sudden cardiac
death. Recently, Schunkert et a! [19], using electrocardiographic
criteria, identified the DD genotype of ACE as a potential genetic
marker associated with an elevated risk of left ventricular hyper-
trophy in middle-aged men. Other potential factors associated
with the development of LVH were not found relevant in this
study. To date, however, the association between LVH, as as-
sessed by echocardiographic criteria, and an insertion (I) deletion
(D) polymorphism of the ACE has not been studied in renal
transplant patients.
Of the many factors analyzed in our study, only the ACE
genotype predicted the changes of left ventricular mass 12 months
after renal transplantation. In fact, although patients with the DD
genotype underwent transplantation with a similar LV mass than
those with the ID or II alleles, they ended the study with
12
significantly greater LV mass, and as a result, a greater proportion
of them met the criteria for LVH. The fact that both groups had
similar LV mass before transplantation could be due to the
presence of uremia-related factors that might override the genetic
predisposition. Volume overload, chronic anemia, arteriovenous
fistula, and intermyocardiocytic fibrosis, among others, are known
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to induce ventricular mass enlargement [5]. The high prevalence
of LVH in uremic patients (> 60%) supports this view [5, 6]. After
renal transplantation many of these factors are eliminated, and
genetic factors may play a more important role in this situation.
Although the functional significance of the ACE polymorphism
is not completely understood, higher ACE levels have been
reported in DD patients [18], which in turn might increase
angiotensin II production and bradykinin degradation. These two
peptide hormones have opposite effects in the modulation of
cardiac growth. Angiotensin II can influence oncogene expression
such as mas-oncogene, c-myc, c-fos, and c-fun, which are known to
be growth regulators [33]. Indeed, experimental studies suggest
that angiotensin II may stimulate myocyte growth, fibroblast
collagen expression and cardiac protein synthesis [14, 15], whereas
bradykinin may have an antiproliferative effect [34]. Since the
components of the renin-angiotensin axis are all expressed in the
heart, the local effects of this system may be more important than
the circulating ones [21, 35]. This hypothesis is supported by
recent data demonstrating that ACE inhibitors, given in very low
doses that do not affect blood pressure, prevented the develop-
ment of cardiac hypertrophy in pressure-overloaded rats [36].
Our finding of an association between the ACE genotype and
the pattern of LV mass changes after renal transplantation may
have important implications in targeting prophylactic interven-
tions. In this regard, it is of interest to note that in a recent
meta-analysis study, ACE inhibitors have been shown to be
superior to some other antihypertensive agents in inducing regres-
sion of cardiac hypertrophy [37]. Whether early administration of
an ACE inhibitor in DD homozygotes has beneficial effects on
LVH in renal transplant patients remains to be determined.
An improvement of systolic (LVEF) and diastolic (LVIRT)
function after renal transplantation, was observed only in patients
with the favorable genotypes (ID or II), although LV mass
remained unchanged. A similar echocardiographic pattern has
been previously reported in this situation, although the genetic
influence was not investigated [12, 13, 38]. It is possible that, in
addition to the removal of uremic toxins after renal transplanta-
tion, a lesser trophic effect of angiotensin II on the interstium and
myocardiocytes allows a better myocardial relaxation in ID or II
patients. The fact that an infusion of angiotensin II in humans
produces a dose-related prolongation of LVIRT supports this
hypothesis [39]. Nevertheless, other diastolic function abnormal-
ities persisted in both groups during the follow-up. It may well be
that environmental factors such as increased blood pressure also
influence the diastolic function.
Several factors in the process of transplantation such as obesity
and arterial hypertension had been associated with LVH [40, 41].
Anti-rejection therapy could be also involved in the development
of LVH. Corticosteroids have been shown to induce ACE gene
expression in vascular smooth muscle [42], and CsA treatment has
been linked to a more severe form of LVH than the one present
in essential hypertension [43]. In our study, however, these factors
were not different for the two groups during follow up. In
agreement with these results, previous studies were also unable to
detect any correlation between ACE polymorphism and blood
pressure [19, 44]. It is also possible that the deleterious effect of
the DD genotype might be restricted to certain vascular territories
like coronary circulation or the atheromatosus arteries [45]. Like
in other multifactorial diseases, the phenotypic expression is
substantially affected by environmental factors. Thus, the genetic
predisposition to achieve higher left ventricular mass linked to the
DD genotype could be more evident in renal transplant patients
who are immunosuppressed with potentially deleterious drugs,
such as corticosteroids and cyclosporine, and frequently suffer
hypertension.
In conclusion, polymorphism of the ACE gene may modulate
changes of left ventricular mass in renal transplant patients. If
these results are confirmed, they may represent the identification
of a new, independent genetic risk factor, which could contribute
to the high occurrence of cardiovascular mortality in these
patients. Moreover, this finding may have important implications
in targeting prophylactic interventions.
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